skip navigation

Skip Nav

Clinical Guidelines Portal

Clinical Guidelines Portal

Table of Contents

Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States

Appendix A: Review of Clinical Trials of Antiretroviral Interventions to Prevent Perinatal HIV Transmission

(Last updated: March 28, 2014; last reviewed: March 28, 2014)

One of the major achievements in HIV research was the demonstration by the Pediatric AIDS Clinical Trials Group 076 (PACTG 076) clinical trial that administration of zidovudine to pregnant women and their infants could reduce risk of perinatal transmission by nearly 70%.1 Following the results of PACTG 076, researchers began to explore the development of shorter, less expensive prophylactic regimens more applicable to resource-constrained settings. A number of regimens have been identified that are effective in reducing perinatal transmission in resource-limited countries (see Supplemental Table 1). This Appendix provides a table summarizing results of major studies of antiretroviral (ARV) prophylaxis to prevent perinatal transmission and a brief discussion of lessons learned. In many cases, direct comparison of results from trials of these regimens is not possible because the studies involved diverse patient populations residing in different geographic locations, infected with diverse viral subtypes, and with different infant feeding practices. However, some generalizations are relevant to understanding use of ARV drugs for prevention of perinatal transmission in both resource-limited and resource-rich countries.

Combination antenatal prophylaxis taken over a longer duration is more effective than a short-course single-drug regimen in reducing perinatal transmission.

The use of ARV drugs to prevent transmission is highly effective, even in HIV-infected women with advanced disease.2,3 Efficacy has been demonstrated for a number of short-course ARV regimens, including those with zidovudine alone; zidovudine plus lamivudine; single-dose nevirapine; and single-dose nevirapine combined with either short-course zidovudine or zidovudine/lamivudine.4-13 In general, combination regimens are more effective than single-drug regimens in reducing perinatal transmission. In addition, for prevention of perinatal transmission, administration of ARV drugs during the antepartum, intrapartum, and postpartum periods is superior to administration of ARV drugs only during the antepartum and intrapartum periods or intrapartum and postpartum periods.5,14,15

Almost all trials in resource-limited countries have included oral intrapartum prophylaxis, with varying durations of maternal antenatal and/or infant (and sometimes maternal) postpartum prophylaxis. Perinatal transmission is reduced by regimens with antenatal components starting as late as 36 weeks’ gestation and lacking an infant prophylaxis component.10-12 However, longer-duration antenatal ARV prophylaxis is more effective than shorter-duration ARV prophylaxis.13 The European National Study of HIV in Pregnancy and Childhood demonstrated that each additional week of a triple-drug regimen corresponded to a 10% reduction in risk of transmission.16 More prolonged infant post-exposure prophylaxis does not appear to substitute for longer-duration maternal ARV prophylaxis.13

No trials have directly compared the efficacy of zidovudine plus single-dose nevirapine with a triple-drug ARV regimen for prevention of in utero transmission in women with higher CD4 T lymphocyte (CD4) cell counts. In African women with CD4 cell counts ranging from 200 to 500 cells/mm3, the Kesho Bora trial compared a triple-ARV drug prophylaxis regimen with zidovudine plus single-dose nevirapine prophylaxis, both started at 28 weeks’ gestation or later, with women in the triple-drug arm continuing the drugs until breastfeeding ceased; those in the zidovudine/single-dose nevirapine arm did not receive postnatal prophylaxis. Although the rate of postnatal transmission was significantly lower in the triple-drug arm than in the zidovudine/single-dose nevirapine arm without postnatal prophylaxis, the rates of transmission at birth were similar in women randomized to a triple-drug regimen (1.8%) and women randomized to antepartum zidovudine/single-dose nevirapine (2.5%); for women with CD4 cell counts from 350 to 500 cells/mm3, the rate of infection at birth was 1.7% in each arm.17 However, the study was not powered to address equivalence between regimens in preventing in utero infection in women with higher CD4 cell counts and the drugs in both arms were administered antepartum for only 6 weeks.

Regimens that do not include maternal ARV prophylaxis during pregnancy have been evaluated because some women may lack antenatal care and present for prenatal care for the first time when they go into labor. Regimens that include only intrapartum and postpartum drug administration also have been shown to be effective in reducing perinatal transmission.4-6 However, without continued infant post-exposure prophylaxis, intrapartum pre-exposure prophylaxis alone with nucleoside reverse transcriptase inhibitor drugs (zidovudine/lamivudine) is not effective in reducing transmission.5 The SAINT trial demonstrated that intrapartum/postpartum zidovudine/lamivudine and single-dose intrapartum/newborn nevirapine are similar in efficacy and safety.6

Combination infant ARV prophylaxis is recommended in the United States for infants whose mothers have not received antenatal ARV drugs.

In some situations, it may be impossible to administer maternal antepartum and intrapartum therapy and only infant prophylaxis may be an option. In the absence of maternal therapy, the standard infant prophylaxis regimen of 6 weeks of zidovudine was effective in reducing HIV transmission compared with no prophylaxis, based on epidemiologic data in resource-rich countries.18 A trial in Malawi in breastfeeding infants demonstrated that adding 1 week of zidovudine therapy to infant single-dose nevirapine reduced risk of transmission by 36% compared with infant single-dose nevirapine alone.7

To define the optimal infant prophylaxis regimen in the absence of maternal antepartum ARV drug administration in a formula-fed population of infants such as in the United States, the NICHD-HPTN 040/P1043 (NCT00099359) clinical trial compared 3 infant ARV regimens in formula-fed infants born to mothers who did not receive ARV drugs during the current pregnancy: standard 6 weeks of zidovudine alone versus 6 weeks of zidovudine plus 3 doses of nevirapine given in the first week of life (first dose birth to 48 hours; second dose 48 hours after first dose; third dose 96 hours after second dose) versus 6 weeks of zidovudine plus lamivudine and nelfinavir given from birth through age 2 weeks.19 The study demonstrated that both the dual and triple combination regimens reduced risk of intrapartum transmission by approximately 50% compared with infant prophylaxis with zidovudine alone, although there was more hematologic toxicity with the triple regimen (see Supplemental Table 1). Based on these data, combination ARV prophylaxis is now recommended in the United States for infants whose mothers have not received antenatal ARV drugs, with the dual regimen of zidovudine plus 3 doses of nevirapine in the first week of life being preferred due to lower rates of toxicity (see Infant Antiretroviral Prophylaxis).

Adding single-dose intrapartum nevirapine is not recommended for women in the United States who are receiving standard recommended antenatal ARV prophylaxis.

Several studies in formula-fed and breastfed populations in resource-limited countries have found that adding maternal/infant single-dose nevirapine to a maternal short-course zidovudine or zidovudine/lamivudine regimen increased efficacy compared with the short-course regimen alone.15,20,21 However, PACTG 316, a clinical trial conducted in the United States, Europe, Brazil, and the Bahamas, demonstrated that for non-breastfeeding women in resource-rich countries, the addition of single-dose nevirapine did not offer significant benefit in the setting of combination ARV prophylaxis throughout pregnancy and very low viral load at the time of delivery.22 Thus, adding single-dose intrapartum nevirapine is not recommended for women in the United States who are receiving standard recommended antenatal ARV prophylaxis (see Intrapartum Antiretroviral Therapy/Prophylaxis).

Breastfeeding by HIV-infected women is not recommended in the United States.

Breastfeeding by HIV-infected women (including those receiving ARV drugs) is not recommended in the United States where replacement feeding is affordable, feasible, acceptable, sustainable, and safe and the risk of infant mortality due to diarrheal and respiratory infections is low.23 Clinical trials have demonstrated that both infant prophylaxis (primarily using daily infant nevirapine) during breastfeeding and maternal triple-drug prophylaxis during breastfeeding decrease postnatal infection (see Supplemental Table 1).2,17,24-29 However, maternal triple-drug prophylaxis may be less effective than infant prophylaxis if the maternal regimen is first started postpartum or late in pregnancy because it takes several weeks to months before full viral suppression in breast milk is achieved.28,30 Importantly, although significantly lowering the risk of postnatal infection, neither infant nor maternal postpartum ARV prophylaxis completely eliminates the risk of HIV transmission through breast milk. Therefore, breastfeeding is not recommended for HIV-infected women in the United States (including those receiving combination ARV drug regimens).23 Finally, both infant nevirapine prophylaxis and maternal triple-drug prophylaxis during breastfeeding may be associated with development of ARV drug resistance in infants who become infected despite prophylaxis; multi-class drug resistance has been described in breastfeeding infants infected despite maternal triple-drug prophylaxis.31-35 

Click here to view this table as an image

Supplemental Table 1. Results of Major Studies on Antiretroviral Prophylaxis to Prevent Perinatal HIV Transmission
Study;
Location(s);
Mode of Infant Feeding
Antiretroviral Drugs Antepartum and Intrapartum Postpartum Perinatal Transmission Rate and Efficacy
PACTG 076; United States, France;1 Formula feeding ZDV vs. placebo Long (from 14 weeks)

IV IP
Long (6 weeks); infant only Perinatal transmission at 18 months was 8.3% in ZDV arm vs. 25.5% in placebo arm (68% efficacy).
CDC short-course ZDV trial;
Thailand;12
Formula feeding
ZDV vs. placebo Short (from 36 weeks)

Oral IP
None Perinatal transmission at 6 months was 9.4% in ZDV arm vs. 18.9% in placebo arm (50% efficacy).
DITRAME (ANRS 049a) trial;
Ivory Coast, Burkina Faso;11,36 Breastfeeding
ZDV vs. placebo Short (from 36 weeks)

Oral IP
Short (1 week); mother only Perinatal transmission was 18.0% in ZDV arm vs. 27.5% in placebo arm at 6 months (38% efficacy) and 21.5% vs. 30.6% at 15 months (30% efficacy).

Perinatal transmission was 22.5% in ZDV arm vs. 30.2% in placebo arm in pooled analysis at 24 months (26% efficacy). 
CDC short-course ZDV trial; Ivory Coast;10,11 Breastfeeding ZDV vs. placebo Short (from 36 weeks)

Oral IP
None Perinatal transmission was 16.5% in ZDV arm vs. 26.1% in placebo arm at 3 months (37% efficacy).

Perinatal transmission was 22.5% in ZDV arm vs. 30.2% in placebo arm in pooled analysis at 24 months (26% efficacy).
PETRA trial; South Africa, Tanzania, and Uganda;5 Breastfeeding and formula feeding AP/IP/PP ZDV + 3TC 
vs.
IP/PP ZDV + 3TC
vs.
IP-only ZDV + 3TC
vs. 
placebo
Short (from 36 weeks)

Oral IP
Short (1 week); mother and infant Perinatal transmission was 5.7% at 6 weeks for AP/IP/PP ZDV + 3TC, 8.9% for IP/PP ZDV + 3TC, 14.2% for IP-only ZDV + 3TC, and 15.3% for placebo (efficacy compared with placebo: 63%, 42%, and 0%, respectively).

Perinatal transmission was 14.9% at 18 months for AP/IP/PP ZDV + 3TC, 18.1% for IP/PP ZDV + 3TC, 20.0% for IP-only ZDV + 3TC, and 22.2% for placebo (efficacy compared with placebo: 34%, 18%, and 0%, respectively).
HIVNET 012 trial; Uganda;4 Breastfeeding SD NVP vs. ZDV No AP ARV

Oral IP: SD NVP vs. oral ZDV
SD NVP within 72 hours of birth, infant only vs. ZDV (1 week); infant only Perinatal transmission was 11.8% in NVP arm vs. 20.0% in ZDV arm at 6–8 weeks (42% efficacy); 15.7% in NVP arm vs. 25.8% in ZDV arm at 18 months (41% efficacy).
SAINT trial; South Africa;6 Breastfeeding and formula feeding SD NVP vs. ZDV + 3TC No AP ARV

Oral IP: SD NVP vs. ZDV + 3TC
SD NVP within 48 hours of birth, mother and infant vs. ZDV + 3TC (1 week); mother and infant Perinatal transmission was 12.3% in SD NVP arm vs. 9.3% in ZDV + 3TC arm at 8 weeks (difference not statistically significant, P = 0.11).
Perinatal HIV Prevention Trial (PHPT-1); Thailand;13 Formula feeding Four ZDV regimens with different durations of AP and infant PP administration; no placebo Long (from 28 weeks), short (from 36 weeks)

Oral IP
Long (6 weeks), short (3 days); infant only Short-short arm stopped at interim analysis (10.5%). Perinatal transmission was 6.5% in long-long arm vs. 4.7% in long-short arm and 8.6% in short-long arm at 6 months (no statistical difference). In utero transmission was significantly higher with short vs. long maternal therapy regimens (5.1% vs. 1.6%).
PACTG 316 trial; Bahamas, Belgium, Brazil, France, Germany, Italy, Spain, Sweden, Switzerland, United Kingdom, United States;22 Formula feeding SD NVP vs. placebo among women already receiving ZDV alone (23%) or ZDV + other ARV drugs (77% combination therapy) Non-study ARV regimen

Oral IP: placebo vs. SD NVP + IV ZDV
Placebo vs. SD NVP within 72 hours of birth + nonstudy ARV drugs (ZDV); infant only 77% of women received dual- or triple-combination ARV regimens during pregnancy.

Trial stopped early because of very low perinatal transmission in both arms: 1.4% in SD NVP arm vs. 1.6% in placebo arm (53% of perinatal transmission was in utero).
Perinatal HIV Prevention Trial (PHPT-2); Thailand;20 Formula feeding ZDV alone 
vs.
ZDV + maternal and infant SD NVP
vs.
ZDV + maternal SD NVP
ZDV from 28 weeks

Oral IP: ZDV alone or ZDV + SD NVP
ZDV for 1 week with or without SD NVP; infant only ZDV-alone arm was stopped because of higher perinatal transmission than the NVP-NVP arm (6.3% vs. 1.1%). In arms in which the mother received SD NVP, perinatal transmission rate did not differ significantly between the infant receiving or not receiving SD NVP (2.0% vs. 2.8%).
DITRAME Plus (ANRS 1201.0) trial; Ivory Coast;15 Breastfeeding and formula feeding Open label, ZDV + SD NVP ZDV from 36 weeks

Oral IP: ZDV plus SD NVP
SD NVP + ZDV for 1 week; infant only Perinatal transmission was 6.5% (95% CI, 3.9%–9.1%) at 6 weeks; perinatal transmission for historical control group receiving short ZDV (98% breastfed) was 12.8%. 
DITRAME Plus (ANRS 1201.1) trial; Ivory Coast;15 Breastfeeding and formula feeding Open label, ZDV + 3TC + SD NVP ZDV + 3TC from 32 weeks (stopped at 3 days PP)

Oral IP: ZDV + 3TC + SD NVP
SD NVP + ZDV for 1 week; infant only Perinatal transmission was 4.7% (95% CI, 2.4%–7.0%) at 6 weeks; perinatal transmission for historical control group receiving short ZDV (98% breastfed) was 12.8%.
NVAZ trial; Malawi;7 Breastfeeding Neonatal SD NVP vs. SD NVP + ZDV No AP or IP ARV (latecomers) SD NVP with or without ZDV for 1 week; infant only  Perinatal transmission was 15.3% in SD NVP + ZDV arm and 20.9% in SD NVP-only arm at 6–8 weeks.

Perinatal transmission rate at 6–8 weeks among infants who were HIV uninfected at birth was 7.7% and 12.1%, respectively (36% efficacy).
    
Postnatal NVP + ZDV trial; Malawi;8 Breastfeeding Neonatal SD NVP vs. SD NVP + ZDV  No AP ARV

Oral IP: SD NVP
SD NVP with or without ZDV for 1 week; infant only Perinatal transmission was 16.3% in NVP + ZDV arm and 14.1% in SD NVP-only arm at 6–8 weeks (difference not statistically significant). 

Perinatal transmission rate at 6–8 weeks among infants who were HIV uninfected at birth was 6.5% and 16.9%, respectively.
Post-Exposure Infant Prophylaxis; South Africa;9 Breastfeeding and formula feeding Neonatal SD NVP vs. ZDV for 6 weeks No AP or IP ARV SD NVP vs. ZDV for 6 weeks For formula-fed infants only, perinatal transmission was 14.3% in SD NVP arm vs. 14.1% in ZDV arm at 6 weeks (not significant, P = 0.30). For breastfed infants only, perinatal transmission was 12.2% in SD NVP arm and 19.6% in ZDV arm (P = 0.03).
Mashi; Botswana;21,37 Breastfeeding and formula feeding Initial: short-course ZDV with/without maternal and infant SD NVP and with/without breastfeeding

Revised: short-course ZDV + infant SD NVP with/without maternal SD NVP and with/without breastfeeding; women with CD4 cell counts <200 cells/mm3 receive combination therapy
First Randomization: ZDV from 34 weeks

Oral IP: ZDV + either SD NVP or placebo
Second Randomization: Breastfeeding + ZDV (infant) 6 months + SD NVP; infant only
vs.
Formula feeding + ZDV (infant) 4 weeks + SD NVP; infant only
Initial Design: In formula-feeding arm, perinatal transmission at 1 month was 2.4% in maternal and infant SD NVP arm and 8.3% in placebo arm (P = 0.05). In breastfeeding + infant ZDV arm, perinatal transmission at 1 month was 8.4% in SD NVP arm and 4.1% in placebo arm (difference not statistically significant).

Revised Design: Perinatal transmission at 1 month was 4.3% in maternal + infant SD NVP arm and 3.7% in maternal placebo + infant SD NVP arm (no significant difference; no interaction with mode of infant feeding).

Perinatal transmission at 7 months was 9.1% in breastfeeding + ZDV arm and 5.6% in formula-feeding arm; mortality at 7 months was 4.9% in breastfeeding + ZDV arm vs. 9.3% in formula-feeding arm; HIV-free survival at 18 months was 15.6% breastfeeding + ZDV arm versus 14.2% formula-feeding arm.
SWEN; Uganda, Ethiopia, India;25 Breastfeeding SD NVP vs. NVP for 6 weeks No AP ARV

Oral IP: SD NVP
Infant SD NVP vs. NVP for 6 weeks Postnatal Infection in Infants Uninfected at Birth:
  • Perinatal transmission at 6 weeks was 5.3% in SD NVP arm vs. 2.5% in extended NVP arm (risk ratio 0.54, P = 0.009).
  • Perinatal transmission at 6 months was 9.0% in SD NVP arm vs. 6.9% in extended NVP arm (risk ratio 0.80, P = 0.16).
HIV-free survival was significantly lower in extended NVP arm at both 6 weeks and 6 months of age.
PEPI-Malawi Trial; Malawi;24 Breastfeeding SD NVP + ZDV for 1 week (control) vs. two extended infant regimens (NVP or NVP/ZDV) for 14 weeks No AP ARV

Oral IP: SD NVP (if mother presents in time)
Infant SD NVP + ZDV for 1 week (control) vs. control + NVP for 14 weeks vs. control + NVP/ZDV for 14 weeks Postnatal Infection in Infants Uninfected at Birth:
  • Perinatal transmission at age 6 weeks was 5.1% in control vs. 1.7% in extended NVP (67% efficacy) and 1.6% in extended NVP/ZDV arms (69% efficacy).
  • Perinatal transmission at age 9 months was 10.6% in control vs. 5.2% in extended NVP (51% efficacy) and 6.4% in extended NVP/ZDV arms (40% efficacy).
No significant difference in perinatal transmission between the extended prophylaxis arms; however, more hematologic toxicity with NVP/ZDV.
MITRA; Tanzania;27 Breastfeeding Infant 3TC for 6 months (observational) ZDV/3TC from 36 weeks through labor Maternal ZDV/3TC for 1 week, infant 3TC for 6 months Perinatal transmission at age 6 months was 4.9% (postnatal perinatal transmission between ages 6 weeks and 6 months was 1.2%).
Kisumu Breastfeeding Study (KiBS); Kenya;29 Breastfeeding    Maternal triple-drug prophylaxis
(observational) 
ZDV/3TC/NVP (NFV if CD4 cell count >250 cells/mm3) from 34 weeks through labor Maternal ZDV/3TC/NVP (NFV if CD4-cell count >250 cells/mm3) for 6 months, infant SD NVP Perinatal transmission at age 6 months was 5.0% (postnatal perinatal transmission between ages 7 days and 6 months was 2.6%).
MITRA-PLUS; Tanzania;26 Breastfeeding Maternal triple-drug prophylaxis (observational) ZDV/3TC/NVP (NFV if CD4 cell count >200 cells/mm3) from 34 weeks through labor Maternal ZDV/3TC/NVP (NFV if CD4-cell count >200 cells/mm3) for 6 months, infant ZDV/3TC for 1 week Perinatal transmission at age 6 months was 5.0% (postnatal perinatal transmission between ages 6 weeks and 6 months was 0.9%), not significantly different from 6-month infant prophylaxis in MITRA.
Kesho Bora; Multi-African;17 Breastfeeding primarily Antepartum ZDV/SD NVP with no postnatal prophylaxis vs. maternal triple-drug prophylaxis in women with CD4 cell counts of 200–500 cells/mm3 Arm 1: ZDV/3TC/LPV/r

Arm 2: ZDV + SD NVP

From 28 weeks through labor
Arm 1: Maternal ZDV/3TC/LPV/r for 6 months, infant SD NVP + ZDV for 1 week

Arm 2: Maternal ZDV/3TC for 1 week (no further postnatal prophylaxis), infant SD NVP + ZDV for 1 week (no further postnatal prophylaxis)
Perinatal transmission at birth was 1.8% with maternal triple-drug prophylaxis Arm 1 and 2.5% with ZDV/SD NVP Arm 2, not significantly different. In women with CD4 cell counts 350–500 cells/mm3, perinatal transmission at birth was 1.7% in both arms.

Perinatal transmission at age 12 months was 5.4% with maternal triple-drug prophylaxis Arm 1 and 9.5% with ZDV/SD NVP (with no further postnatal prophylaxis after 1 week) Arm 2 (P = 0.029).
Mma Bana; Botswana;2 Breastfeeding Maternal triple-drug prophylaxis (compares 2 regimens) in women with CD4 cell counts >200 cells/mm3 Arm 1: ZDV/3TC/ABC

Arm 2: ZDV/3TC/LPV/r

From 26 weeks through labor
Arm 1: Maternal ZDV/3TC/ABC for 6 months, infant SD NVP + ZDV for 4 weeks

Arm 2: Maternal ZDV/3TC/LPV/r for 6 months, infant SD NVP + ZDV for 4 weeks
Perinatal transmission at age 6 months overall was 1.3%: 2.1% in ZDV/3TC/ABC Arm 1 and 0.4% in ZDV/3TC/LPV/r Arm 2 (P = 0.53).
BAN; Malawi;28,38 Breastfeeding Postpartum maternal triple-drug prophylaxis vs. infant NVP in women with CD4 cell counts ≥250 cells/mm3 No AP drugs

IP regimens:

Arm 1 (control): ZDV/3TC + SD NVP

Arm 2: ZDV/3TC + SD NVP

Arm 3: ZDV/3TC + SD NVP
Arm 1 (Control): Maternal ZDV/3TC for 1 week, infant SD NVP + ZDV/3TC for 1 week

Arm 2: Control as above, then maternal ZDV/3TC/LPV/r for 6 months

Arm 3: Control as above, then infant NVP for 6 months
Postnatal Infection in Infants Uninfected at Age 2 Weeks:
  • Perinatal transmission at age 28 weeks was 5.7% in control Arm 1; 2.9% in maternal triple-drug prophylaxis Arm 2 (P = 0.009 vs. control); 1.7% in infant NVP Arm 3 (P <0.001 vs. control).
  • Perinatal transmission at age 48 weeks was 7.0% in control Arm 1; 4% in maternal triple-drug prophylaxis Arm 2 (P = 0.0273 vs. control); 4% in infant NVP Arm 3 (P = 0.0027 vs. control).
No significant difference between maternal triple-drug prophylaxis Arm 2 and infant NVP Arm 3 (P = 0.12 at 28 weeks and P = 0.426 at 48 weeks).
HPTN 046; South Africa, Tanzania, Uganda, Zimbabwe;35 Breastfeeding Postpartum prophylaxis of breast milk transmission of HIV with 6 weeks vs. 6 months of infant NVP AP drugs allowed if required for maternal health All infants received daily NVP from birth through age 6 weeks.

Arm 1: Daily infant NVP from 6 weeks through 6 months of age

Arm 2: Daily infant placebo from age 6 weeks through age 6 months
In infants uninfected at age 6 weeks, the 6-month infant HIV infection rate was 1.1% (0.3%–1.8%) in the extended NVP Arm 1 and 2.4% (1.3%–3.6%) in the placebo Arm 2 (P = 0.048).

At infant randomization at age 6 weeks, 29% of mothers in each arm were receiving a triple-drug ARV regimen for treatment of HIV.

For mothers receiving triple-drug ARV regimens at the time of randomization, in infants uninfected at age 6 weeks, the 6-month infant HIV infection rate was 0.2% and not statistically different between extended NVP Arm 1 (0.5%) and placebo Arm 2 (0%).

For mothers with CD4 cell counts >350 cells/mm3 who were not receiving triple-drug ARV regimens, in infants uninfected at age 6 weeks, the 6-month infant HIV infection rate was 0.7% (0%–1.5%) in the extended NVP Arm 1 and 2.8% (1.3%–4.4%) in the placebo Arm 2 (P = 0.014).
NICHD-HPTN 040/PACTG 1043 trial; Argentina, Brazil, South Africa, United States;19 Formula feeding Infant prophylaxis with 6 weeks ZDV
vs.
6 weeks infant ZDV plus three doses of NVP in first week of life
vs.
6 weeks infant ZDV plus 2 weeks of 3TC/NFV
No AP drugs

If mother presented early enough, IV ZDV during labor through delivery
Arm 1 (control): Infant ZDV for 6 weeks

Arm 2: Control as above plus NVP with first dose within 48 hours of birth, second dose 48 hours later, and third dose 96 hours after the second dose

Arm 3: Control as above, plus 3TC and NFV from birth through 2 weeks of age
IP HIV transmission among infants with negative HIV test at birth: 4.8% (3.2%–7.1%) ZDV (Arm 1) vs. 2.2% (1.2%–3.9%) in ZDV plus NVP (Arm 2) (P = 0.046 compared with Arm 1) vs. 2.4% (1.4%–4.3%) in ZDV plus 3TC/NFV (Arm 3) (P = 0.046 compared with Arm 1).

Overall HIV transmission rates, including in utero infection: 11.0% (8.7%–14.0%) ZDV (Arm 1) vs. 7.1% (5.2%–9.6%) in ZDV plus NVP (Arm 2) (P = 0.035 compared with Arm 1) vs. 7.4% (5.4%–9.9%) in ZDV plus 3TC/NFV (Arm 3) (P = 0.035 compared with Arm 1).

Grade 3 or 4 neutropenia more frequent in ZDV/3TC/NFV Arm 3, 70 infants, compared with ZDV alone Arm 1, 33 infants, or ZDV/NVP Arm 2, 32 infants (P <0.001).
Key to Acronyms: 3TC = lamivudine; ABC = abacavir; AP = antepartum; ARV = antiretroviral; CDC = Centers for Disease Control and Prevention; CI = confidence interval; IP = intrapartum; IV = intravenous; LPV/r = ritonavir-boosted lopinavir; NFV = nelfinavir; NVP = nevirapine; PP = postpartum; SD = single-dose; ZDV = zidovudine

References

  1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med.1994;331(18):1173-1180. Available at http://www.ncbi.nlm.nih.gov/pubmed/7935654.
  2. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010;362(24):2282-2294. Available at http://www.ncbi.nlm.nih.gov/pubmed/20554983.
  3. Kesho Bora Study G. Eighteen-month follow-up of HIV-1-infected mothers and their children enrolled in the Kesho Bora study observational cohorts. J Acquir Immune Defic Syndr. 2010;54(5):533-541. Available at http://www.ncbi.nlm.nih.gov/pubmed/20543706.
  4. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362(9387):859-868. Available at http://www.ncbi.nlm.nih.gov/pubmed/13678973.
  5. Petra Study T. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet. 2002;359(9313):1178-1186. Available at http://www.ncbi.nlm.nih.gov/pubmed/11955535.
  6. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 2003;187(5):725-735. Available at http://www.ncbi.nlm.nih.gov/pubmed/12599045.
  7. Taha TE, Kumwenda NI, Gibbons A, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet. 2003;362(9391):1171-1177. Available at http://www.ncbi.nlm.nih.gov/pubmed/14568737.
  8. Taha TE, Kumwenda NI, Hoover DR, et al. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA. 2004;292(2):202-209. Available at http://www.ncbi.nlm.nih.gov/pubmed/15249569.
  9. Gray GE, Urban M, Chersich MF, et al. A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. AIDS. 2005;19(12):1289-1297. Available at http://www.ncbi.nlm.nih.gov/pubmed/16052084.
  10. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet. 1999;353(9155):781-785. Available at http://www.ncbi.nlm.nih.gov/pubmed/10459958.
  11. Leroy V, Karon JM, Alioum A, et al. Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa. AIDS. 2002;16(4):631-641. Available at http://www.ncbi.nlm.nih.gov/pubmed/11873008.
  12. Shaffer N, Chuachoowong R, Mock PA, et al, with the Bangkok Collaborative Perinatal HIV Transmission Study Group. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet. 1999;353(9155):773-780. Available at http://www.ncbi.nlm.nih.gov/pubmed/10459957.
  13. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med. 2000;343(14):982-991. Available at http://www.ncbi.nlm.nih.gov/pubmed/11018164.
  14. Leroy V, Sakarovitch C, Cortina-Borja M, et al. Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa? AIDS. 2005;19(16):1865-1875. Available at http://www.ncbi.nlm.nih.gov/pubmed/16227795.
  15. Dabis F, Bequet L, Ekouevi DK, et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS. 2005;19(3):309-318. Available at http://www.ncbi.nlm.nih.gov/pubmed/15718842.
  16. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS. 2008;22(8):973-981. Available at http://www.ncbi.nlm.nih.gov/pubmed/18453857.
  17. Kesho Bora Study G, de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis. 2011;11(3):171-180. Available at http://www.ncbi.nlm.nih.gov/pubmed/21237718.
  18. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 1998;339(20):1409-1414. Available at http://www.ncbi.nlm.nih.gov/pubmed/9811915.
  19. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med. 2012;366(25):2368-2379. Available at http://www.ncbi.nlm.nih.gov/pubmed/22716975.
  20. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004;351(3):217-228. Available at http://www.ncbi.nlm.nih.gov/pubmed/15247338.
  21. Shapiro RL, Thior I, Gilbert PB, et al. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS. 2006;20(9):1281-1288. Available at http://www.ncbi.nlm.nih.gov/pubmed/16816557.
  22. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 2002;288(2):189-198. Available at http://www.ncbi.nlm.nih.gov/pubmed/12095383.
  23. Committee on Pediatric AIDS. Infant feeding and transmission of human immunodeficiency virus in the United States. Pediatrics. 2013;131(2):391-396. Available at http://www.ncbi.nlm.nih.gov/pubmed/23359577.
  24. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med. 2008;359(2):119-129. Available at http://www.ncbi.nlm.nih.gov/pubmed/18525035.
  25. Six Week Extended-Dose Nevirapine Study T, Bedri A, Gudetta B, et al. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet. 2008;372(9635):300-313. Available at http://www.ncbi.nlm.nih.gov/pubmed/18657709.
  26. Kilewo C, Karlsson K, Ngarina M, et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr. 2009;52(3):406-416. Available at http://www.ncbi.nlm.nih.gov/pubmed/19730269.
  27. Kilewo C, Karlsson K, Massawe A, et al. Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J Acquir Immune Defic Syndr. 2008;48(3):315-323. Available at http://www.ncbi.nlm.nih.gov/pubmed/18344879.
  28. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010;362(24):2271-2281. Available at http://www.ncbi.nlm.nih.gov/pubmed/20554982.
  29. Thomas TK, Masaba R, Borkowf CB, et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding--the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med. 2011;8(3):e1001015. Available at http://www.ncbi.nlm.nih.gov/pubmed/21468300.
  30. Mofenson LM. Protecting the next generation--eliminating perinatal HIV-1 infection. N Engl J Med. 2010;362(24):2316-2318. Available at http://www.ncbi.nlm.nih.gov/pubmed/20554987.
  31. Moorthy A, Gupta A, Bhosale R, et al. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS One. 2009;4(1):e4096. Available at http://www.ncbi.nlm.nih.gov/pubmed/19119321.
  32. Fogel JM, Mwatha A, Richardson P, et al.  Impact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants. Pediatr Infect Dis J. 2013;32(4):e164-9.  Available at: http://www.ncbi.nlm.nih.gov/pubmed/23249916.
  33. Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med. 2011;8(3):e1000430. Available at http://www.ncbi.nlm.nih.gov/pubmed/21468304.
  34. Fogel J, Li Q, Taha TE, et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis. 2011;52(8):1069-1076. Available at http://www.ncbi.nlm.nih.gov/pubmed/21460326.
  35. Coovadia HM, Brown ER, Fowler MG, et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;379(9812):221-228. Available at http://www.ncbi.nlm.nih.gov/pubmed/22196945.
  36. Dabis F, Msellati P, Meda N, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la Transmission Mere-Enfant. Lancet. 1999;353(9155):786-792. Available at http://www.ncbi.nlm.nih.gov/pubmed/10459959.
  37. Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA. 2006;296(7):794-805. Available at http://www.ncbi.nlm.nih.gov/pubmed/16905785.
  38. Jamieson DJ, Chasela CS, Hudgens MG, et al. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. Lancet. 2012;379(9835):2449-2458. Available at http://www.ncbi.nlm.nih.gov/pubmed/22541418.

Back to Top